Sarepta Therapeutics (SRPT) Tuesday reported first-quarter net loss of $447.5 million or $4.60 per share, compared to net income of $36.1 million or $0.37 per share in the same period last year.
Excluding items, Sarepta Therapeutics reported adjusted loss of $332.5 million or $3.42 per share for the period.
Research and development expenses were $773.4 million for the three months ended March 31, 2025, as compared to $200.4 million for the same period of 2024, an increase of $573.0 million. The increase in research and development expenses primarily reflects an increase in up-front and milestone expense associated with the licensing and collaboration agreement and stock purchase agreement with Arrowhead, partially offset by a decrease in clinical trial expenses primarily due to the discontinuation of the PPMO programs in 2024.
Revenues for the quarter rose to $744.9 million from $413.5 million in the same period last year.
Looking forward, the company expects net product revenues of $2.30 billion to $2.60 billion, down from prior estimate of $2.90 billion to $3.10 billion.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.